The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
NCT Number: NCT03923296
Iterative co-design study where patients receiving systemic cancer therapy, carers and healthcare professionals involved in delivering cancer therapy, work with Entia to design a home based blood monitoring service. The iterative process means that at each stage of the development process, Entia will be building on what is learnt in the previous stage.
Looking for future studies?
Notify MeThe study will use feedback provided by patients, carers and heatlhcare professionals to inform the changes that are necessary to develop a successful, user friendly home-based blood monitoring service for cancer patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For carers
For healthcare professionals
All participants:-
Exclusion criteria
For patients
For carers
For healthcare professionals
● Doctors who are not employed at Specialist Registrar, Fellow or Consultant Level
Blood from a single fingerprick will be used to used to measure and monitor patients blood parameters.
Focus group interviews
Time frame: 30 months
Participant feedback on the iterative designs of a future home-based monitoring service in order to arrive at a final prototype device and service design, suitable for patient, carer and healthcare professional's use.
Entia Ltd
Industry
PERTH 2: Co-design of a Home-based Monitoring Service for Cancer Patients, Carers and Health Care Professionals to Optimize Delivery of Systemic Therapy.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03739372
Astrocytoma, Cancer
San Diego, California, United States
View Trial DetailsNCT02108028
Cancer, Chronic Disease
Orange, California, United States
View Trial DetailsNCT05156931
Cancer, Neoplasms
Clermont-Ferrand, France
View Trial DetailsNCT07073807
Behavior, Behavioral Symptoms
Irvine, California, United States
View Trial Details